Related Experiment Video
Updated: Oct 18, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple
Zoya G Georgieva1,2, Rainer Dӧffinger3, Dinakantha Kumararatne3
1Department of Clinical Neurosciences, University of Cambridge, Hills Road, Cambridge CB2 0AH, UK.
Background:
Despite impressive efficacy in immunocompetent individuals, the immunogenicity of a single dose of COVID-19 vaccine in B-cell-deplete patients remains unknown.
Objectives:
We aimed to quantify real-world vaccine immunogenicity in ocrelizumab recipients.
Methods:
We measured post-vaccination SARS-COV-2 immunoglobulin G (IgG) in ocrelizumab recipients using a highly sensitive Luminex assay.
Results:
44.1% of patients had detectable SARS-COV-2-IgG 21+ days after one vaccine dose, regardless of vaccine type (AZD1222 vs BNT162b2, odds ratio (OR) = 0.62, 95% confidence interval (CI) = 0.157-2.32, p = 0.72). B-cell count strongly predicted seroconversion (β1 = 12.38, 95% CI = 4.59-20.16, p = 0.0029), but undetectable B-cells did not preclude it. The second vaccine seroconverted 53% of the patients who had not already responded to dose 1.
Conclusion:
Humoral response after one COVID-19 vaccine dose is lower than expected in CD20-deplete patients.
More Related Videos
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

